Sai Duriseti

Title(s)HS Assistant Clinical Professor, Radiation Oncology
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer. World J Urol. 2024 Mar 16; 42(1):165. Nikitas J, Kishan A, Chang A, Duriseti S, Nichols NG, Reiter R, Rettig M, Brisbane W, Steinberg ML, Valle L. PMID: 38492111.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024 Mar 14. Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. PMID: 38490853.
      View in: PubMed   Mentions:    Fields:    
    3. A Dose Accumulation Assessment of Alignment Errors During Spatially Fractionated Radiation Therapy. Pract Radiat Oncol. 2023 Dec 10. Ginn J, Duriseti S, Mazur T, Spraker M, Kavanaugh J. PMID: 38081359.
      View in: PubMed   Mentions:    Fields:    
    4. Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement. Eur J Hybrid Imaging. 2023 Apr 03; 7(1):7. Duriseti S, Berenji G, Tsai S, Rettig M, Nickols NG. PMID: 37009941; PMCID: PMC10068685.
      View in: PubMed   Mentions: 1  
    5. Better Late than Never for Late Toxicity Assessment. Eur Urol. 2023 May; 83(5):391-392. Duriseti S, Berenji GR, Nickols NG, Rettig MB. PMID: 36797143.
      View in: PubMed   Mentions:    Fields:    
    6. Brainstem Toxicity in Pediatric Patients Treated with Protons Using a Single-vault Synchrocyclotron System. Int J Part Ther. 2022; 9(1):12-17. Orukari I, Perkins S, Zhao T, Huang J, Caruthers DF, Duriseti S. PMID: 35774490; PMCID: PMC9238130.
      View in: PubMed   Mentions: 2  
    7. LITE SABR M1: Planning design and dosimetric endpoints for a phase I trial of lattice SBRT. Radiother Oncol. 2022 02; 167:172-178. Kavanaugh JA, Spraker MB, Duriseti S, Basarabescu F, Price A, Goddu M, Knutson N, Prusator M, Robinson C, Mazur T. PMID: 34896459.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    8. LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiother Oncol. 2022 02; 167:317-322. Duriseti S, Kavanaugh JA, Szymanski J, Huang Y, Basarabescu F, Chaudhuri A, Henke L, Samson P, Lin A, Robinson C, Spraker MB. PMID: 34875286.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    9. Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2022 Jan-Feb; 7(1):100797. Schiff JP, Spraker MB, Duriseti S, Shaikh S, Murad HF, Mutch DG, Robinson CG, Kavanaugh J, Lin AJ. PMID: 34761139; PMCID: PMC8567179.
      View in: PubMed   Mentions: 3  
    10. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol. 2021 May-Jun; 6(3):100639. Duriseti S, Kavanaugh J, Goddu S, Price A, Knutson N, Reynoso F, Michalski J, Mutic S, Robinson C, Spraker MB. PMID: 34195486; PMCID: PMC8233471.
      View in: PubMed   Mentions: 12  
    11. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018 Dec; 140(3):629-638. Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S. PMID: 30206764.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    12. Brain metastasis growth on preradiosurgical magnetic resonance imaging. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):e369-e376. Garcia MA, Anwar M, Yu Y, Duriseti S, Merritt B, Nakamura J, Hess C, Theodosopoulos PV, McDermott M, Sneed PK, Braunstein SE. PMID: 30174247.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    13. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes. J Neurosurg. 2017 Jun; 126(6):1756-1763. Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess CP, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott M, Sneed PK, Braunstein S. PMID: 27367235.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    14. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014; 4(3):267-79. LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. PMID: 24505235; PMCID: PMC3915090.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    15. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013 Apr 01; 73(7):2070-81. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. PMID: 23400595; PMCID: PMC3618559.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    16. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem. 2010 Aug 27; 285(35):26878-26888. Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. PMID: 20501655; PMCID: PMC2930687.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    17. Molecular basis of binding of the Plasmodium falciparum receptor BAEBL to erythrocyte receptor glycophorin C. Mol Biochem Parasitol. 2009 Nov; 168(1):49-54. Jiang L, Duriseti S, Sun P, Miller LH. PMID: 19563830; PMCID: PMC2744354.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    18. HOXA5 regulates hMLH1 expression in breast cancer cells. Neoplasia. 2006 Apr; 8(4):250-8. Duriseti S, Winnard PT, Mironchik Y, Vesuna F, Raman A, Raman V. PMID: 16756717; PMCID: PMC1600677.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    19. Allergy-epitomes of progress: immunologic aspects of atopic dermatitis. West J Med. 1977 Nov; 127(5):409. Galant SP, Duriseti S. PMID: 18748085; PMCID: PMC1237885.
      View in: PubMed   Mentions:    Fields:    
    Sai's Networks
    Concepts (103)
    Derived automatically from this person's publications.
    Co-Authors (32)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department